Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the
cancer. Lenalidomide may also stimulate the immune system in different ways and stop cancer
cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways
to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Azacitidine may also cause cancer cells to look more like normal cells, and to grow
and spread more slowly. Giving lenalidomide together with azacitidine may kill more cancer
cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide and
azacitidine in treating patients with advanced myelodysplastic syndromes.